002880.SZ
Shenzhen Weiguang Biological Products Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 20.50
−2.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.3B | 1.2B | 1.0B | 667.9M |
| Cost of Revenue | 773.7M | 768.1M | 699.3M | 615.3M | 427.0M |
| Gross Profit | 489.8M | 498.6M | 503.9M | 433.2M | 240.9M |
| Operating Expenses | |||||
| R&D Expense | 45.6M | 46.0M | 49.1M | 63.6M | 35.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 96.3M | 95.0M | 92.7M | 86.1M | 64.4M |
| Selling & Marketing Expense | 35.1M | 36.1M | 29.1M | 40.9M | 27.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 208.6M | 208.6M | 200.8M | 210.8M | 130.9M |
| Cost and Expenses | 982.3M | 976.7M | 900.1M | 826.1M | 558.0M |
| Operating Income (EBIT) | 270.0M | 284.0M | 296.6M | 247.3M | 138.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 269.2M | 283.0M | 296.7M | 245.5M | 137.3M |
| Income Tax Expense | 36.3M | 37.2M | 42.8M | 27.9M | 16.1M |
| Bottom Line | |||||
| Net Income | 233.5M | 246.3M | 253.5M | 218.7M | 117.5M |
| Earnings from Cont. Ops | 232.8M | 245.8M | 254.0M | 217.5M | 121.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 233.5M | 246.3M | 253.5M | 218.7M | 117.5M |
| Per Share | |||||
| Basic EPS | CN¥1.03 | CN¥1.09 | CN¥1.12 | CN¥0.96 | CN¥0.52 |
| Diluted EPS | CN¥1.03 | CN¥1.09 | CN¥1.12 | CN¥0.96 | CN¥0.52 |
| Revenue Per Share | CN¥5.57 | CN¥5.59 | CN¥5.31 | CN¥4.62 | CN¥2.95 |
| Shares | |||||
| Basic Shares Outstanding | 226.8M | 226.8M | 226.8M | 226.8M | 226.8M |
| Diluted Shares Outstanding | 226.8M | 226.8M | 226.8M | 226.8M | 226.8M |
| Profitability Metrics | |||||
| EBITDA | — | 442.3M | 416.0M | 335.7M | 204.0M |
| D&A | — | 158.3M | 119.3M | 88.4M | 65.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026